Re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial

Eur Urol. 2022 Oct;82(4):441. doi: 10.1016/j.eururo.2022.07.004. Epub 2022 Jul 25.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Randomized Controlled Trial

MeSH terms

  • Androgen Antagonists / therapeutic use
  • Androgens / therapeutic use
  • Disease-Free Survival
  • Humans
  • Male
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / radiotherapy

Substances

  • Androgen Antagonists
  • Androgens
  • Prostate-Specific Antigen